XXIX IACRLRD SYMPOSIUM
IACRLRD 2019
29th International Symposium of the International Association for Comparative Research on Leukemia and Related Diseases
November 7 - 9, 2019
Grand Hyatt Seoul, Korea
ML01Translating DNA Repair for Targeting CancersProf. Kyungjae MyungUNIST / Institute for Basic Science, KoreaCV
ML02Biological Heterogeneity of AML: Implications for Prognosis and TreatmentProf. Clara BloomfieldThe Ohio State University, USACV
ML03Approaching Survival of the General Population: The Results of CML Study IV in the Global ContextProf. Rüdiger HehlmannHeidelberg University, GermanyCV
ML04New Models of Human LeukemiaDr. Connie EavesBritish Columbia Cancer part of Provincial Health Services Authority, CanadaCV
ML05Integrating CAR T-Cell Therapy into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient OutcomesProf. David G. MaloneyFred Hutchinson Cancer Research Center, USACV
ML06Leukemia Stem Cell and Bone Marrow Microenvironment InteractionsProf. Ravi BhatiaThe University of Alabama at Birmingham, USACV
ML07Understanding Evolution and Outcomes in Myeloproliferative NeoplasmsDr. Jyoti NangaliaWellcome Sanger Institute, UKCV
KSA Novel Epigenetic Drug against Adult T-cell LeukemiaProf. Toshiki WatanabeThe University of Tokyo, JapanCV
SY01-1Using HTLV-1/BLV Genomics to Understand Adult T-cell LeukemiaDr. Anne Van den BroekeJules Bordet Institute - ULB, Belgium
SY01-2Hydroa-vacciniforme-like Lymphoproliferative Disease: A Cutaneous Form of CAEBVProf. Young-Hyeh KoSungkyunkwan University, Korea
SY01-3Can We Cure Adult T Cell Leukemia/Lymphoma?Prof. Ali BazarbachiAmerican University of Beirut-Medical Center, LebanonCV
SY02-1DNA Methylation and Hydroxymethylation in Hematologic Differentiation and TransformationProf. Myunggon KoUlsan National Institute of Science and Technology, KoreaCV
SY02-2Iron Toxicity in MDSProf. Daniela CilloniUniversity of Torino, ItalyCV
SY02-3DDX41 Mutations in Myelodysplastic SyndromeProf. Je-Hwan LeeUniversity of Ulsan, KoreaCV
SY02-4Hypomethylation-based Combination Treatments: Where Epigenetics Meets ImmunotherapyProf. Michael LübbertUniversity of Freiburg Medical Center, GermanyCV
LS01TBDProf. Richard ClarkUniversity of Liverpool, UKCV
SY03-1The Rapidly Evolving Landscape in AMLProf. Gert OssenkoppeleAmsterdam University Medical Center, location VUMC, The NetherlandsCV
SY03-2Curative Treatment Options for Older Patients with AMLProf. Hervé DombretSaint-Louis Institute for Research/ University of Paris, FranceCV
SY03-3Development of A Novel FLT3 InhibitorProf. Hitoshi KiyoiNagoya University, JapanCV
SY03-4Functional Genomic Approaches to Identifying New Therapeutic Strategies for AMLProf. Jeffrey TynerOregon Health & Science University, USACV
SY04-1Next Generation Sequencing for Chronic Myeloid LeukemiaProf. Susan BranfordCentre for Cancer Biology, SA Pathology, AustraliaCV
SY04-2New Horizon for CML Therapy: Treatment Discontinuation (TFR)Prof. Giuseppe SaglioUniversity of Torino, ItalyCV
SY04-3TBDProf. Michael MauroMemorial Sloan Kettering Cancer Center, USACV
SY04-4Allogeneic Stem Cell Transplantation in CMLProf. Eduardo OlavarriaImperial College London, UKCV
SY05-1Clinical and Biological Significance of RNA Editing Defect in MyelomaProf. Wee Joo ChngNational University Health System, SingaporeCV
SY05-2Current Approaches and Future Perspectives in the Treatment of Newly Diagnosed Myeloma PatientsProf. Roberto MinaUniversity of Torino, ItalyCV
SY05-3MRD: A Pitfall Between Next Generation Flow and Next Generation SequencingProf. Dong Soon LeeSeoul National University, KoreaCV
SY06-1Analysis of CNS-ALL with Patient Derived Xenografts (PDX) ModelProf. Itaru KatoKyoto University, JapanCV
SY06-2Targeting Cell Adhesion-mediated Resistance in ALLProf. Yong-Mi KimUniversity of Southern California, USACV
SY06-3Minimal Residual Disease and Targeted Therapy in Acute Lymphoblastic LeukemiaProf. Dieter HoelzerOnkologikum Frankfurt, GermanyCV
SY06-4TBDProf. Françoise HuguetUniversity Institute of Cancer, FranceCV
LS02Cutting Edge of Molecular Target Therapy and Therapeutic Strategies in CMLProf. Yosuke MinamiNational Cancer Center Hospital East, JapanCV
SY07-1Understanding and Targeting the Stem Cell Origins of MDS and AMLProf. Ulrich SteidlAlbert Einstein College of Medicine - Montefiore Medical Center, USACV
SY07-2Genetics and Mechanisms of Chemotherapy Resistance in ALLProf. Adolfo FerrandoColumbia University, USACV
SY07-3TBDProf. Seishi OgawaKyoto University, Japan
SY07-4Single-cell Sequencing for Understanding Tumor Heterogeneity and EvolutionProf. Semin LeeUlsan National Institute of Science and Technology, KoreaCV
SY08-1Molecular Predictors and Prognosticators for the Clinical Management of Chronic Lymphocytic LeukemiaProf. Gianluca GaidanoUniversity of Eastern Piedmont, ItalyCV
SY08-2TBDProf. Wei XuJiangsu Province Hospital, ChinaCV
SY08-3Management of NK/T-cell LymphomaProf. Seok Jin KimSamsung Medical Center, KoreaCV
SY08-4TBDProf. Richard A. LarsonThe University of Chicago, USACV
SY09-12020 Clinical, Laboratory, Molecular and Bone Marrow (CLMB) Classification and Treatment Options of Myeloproliferative NeoplasmsProf. Jan Jacques MichielsGoodheart Institute and Foundation, The NetherlandsCV
SY09-2Allogeneic Hematopoietic Stem Cell Transplantation for Primary MyelofibrosisProf. Ki-Seong EomThe Catholic University of Korea, Korea